{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:30:45Z","timestamp":1788395445817,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> In clinical studies, some patients who achieve deep molecular response (DMR) can successfully discontinue tyrosine kinase inhibitor (TKI). TKI dose reduction is also an important aspect of alleviating adverse effects and improving quality of life. This study aimed to explore the outcome after drug withdrawal in Chinese CML patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We conducted a retrospective analysis of the outcome of 190 patients who stopped TKI. 27 patients experienced dose reduction before TKI discontinuation. The median duration of TKI treatment and MR4 before discontinuation was 82\u00a0months and 61\u00a0months.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> With median follow-up after stopping TKI treatment of 17\u00a0months, the estimated TFR (Treatment Free Remission) were 76.9% (95%CI, 70.2%\u201382.4%), 68.8% (95%CI, 61.3%\u201375.2%), and 65.5% (95%CI, 57.4%\u201372.5%) at 6, 12 and 24\u00a0months. For full-dose and low-dose TKI groups, the TFR at 24\u00a0months was 66.7% and 55.8% (<jats:italic>p<\/jats:italic> = 0.320, log-rank). Most patients (56\/57) quickly achieved MMR after restarting TKI treatment. Multivariable analysis showed that patients with TKI resistance had a higher risk of molecular relapse than patients without TKI resistance (<jats:italic>p<\/jats:italic> &amp;lt; 0.001).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> TFR rates were not impaired in patients experiencing dose reduction before TKI discontinuation compared to patients with full-dose TKI. Our data on Chinese population may provide a basis for the safety and feasibility of TKI discontinuation, including discontinuation after dose reduction, in clinical practice.<\/jats:p>","DOI":"10.3389\/fphar.2023.1101743","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T05:01:17Z","timestamp":1674450077000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice"],"prefix":"10.3389","volume":"14","author":[{"given":"Yilin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danlei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanjun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv."},{"key":"B2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.16083","article-title":"Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome","volume":"187","author":"Berger","year":"2019","journal-title":"Br. J. Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1002\/cncr.32940","article-title":"Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study","volume":"126","author":"Cayssials","year":"2020","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.3324\/haematol.2022.280637","article-title":"Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: A retrospective study in China","volume":"107","author":"Chen","year":"2022","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"E310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): An interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"E375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): A non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/bjh.17286","article-title":"TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia","volume":"193","author":"Claudiani","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.3390\/cancers12092521","article-title":"Incidences of deep molecular responses and treatment-free remission in de Novo CP-CML patients","volume":"12","author":"Etienne","year":"2020","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3324\/haematol.2018.194522","article-title":"Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: A simulation study based on phase III trial data","volume":"103","author":"Fassoni","year":"2018","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3324\/haematol.2018.205054","article-title":"Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice","volume":"104","author":"Fava","year":"2019","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/bjh.17392","article-title":"Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry","volume":"193","author":"Flygt","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-018-0125-0","article-title":"Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: Results from a nationwide series of 236 patients","volume":"8","author":"Hernandez-Boluda","year":"2018","journal-title":"Blood Cancer J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"839915","DOI":"10.3389\/fonc.2022.839915","article-title":"Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: A feasible option also in the real-life. A campus CML study","volume":"12","author":"Iurlo","year":"2022","journal-title":"Front. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"E260","DOI":"10.1002\/ajh.25908","article-title":"Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs","volume":"95","author":"Iurlo","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/s41375-021-01306-1","article-title":"Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): A single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/17474086.2019.1623666","article-title":"An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission","volume":"12","author":"Kunbaz","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: The KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/jha2.550","article-title":"De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China","volume":"3","author":"Luo","year":"2022","journal-title":"EJHaem"},{"key":"B20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: Results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann. Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12185-019-02736-5","article-title":"Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: A multicenter phase 2 trial, stop nilotinib (NILSt)","volume":"110","author":"Nagafuji","year":"2019","journal-title":"Int. J. Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin. Lymphoma Myeloma & Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.18553\/jmcp.2019.25.10.1140","article-title":"Tyrosine kinase inhibitors initiation, cost sharing, and health care utilization in patients with newly diagnosed chronic myeloid leukemia: A retrospective claims-based study","volume":"25","author":"Phuar","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"key":"B25","article-title":"Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: A real life observational study (NILO-RED)","volume":"130","author":"Rea","year":"","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","article-title":"Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission","volume":"4","author":"Rousselot","year":"2020","journal-title":"Blood Adv."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1038\/bcj.2015.75","article-title":"Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment","volume":"5","author":"Russo","year":"2015","journal-title":"Blood Cancer J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: Analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: The DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1101743\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T05:01:21Z","timestamp":1674450081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1101743\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":34,"alternative-id":["10.3389\/fphar.2023.1101743"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1101743","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"article-number":"1101743"}}